These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 11871901)

  • 1. Development of versatile cis- and trans-dicarbon-substituted chiral cyclopropane units: synthesis of (1S,2R)- and (1R,2R)-2-aminomethyl-1-(1H-imidazol-4-yl)cyclopropanes and their enantiomers as conformationally restricted analogues of histamine.
    Kazuta Y; Matsuda A; Shuto S
    J Org Chem; 2002 Mar; 67(5):1669-77. PubMed ID: 11871901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
    Kazuta Y; Hirano K; Natsume K; Yamada S; Kimura R; Matsumoto S; Furuichi K; Matsuda A; Shuto S
    J Med Chem; 2003 May; 46(10):1980-8. PubMed ID: 12723960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of a cis-cyclopropane via reductive radical decarboxylation. Enantioselective synthesis of cis- and trans-1-arylpiperazyl-2-phenylcyclopropanes designed as antidopaminergic agents.
    Yamaguchi K; Kazuta Y; Abe H; Matsuda A; Shuto S
    J Org Chem; 2003 Nov; 68(24):9255-62. PubMed ID: 14629144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclopropane-based stereochemical diversity-oriented conformational restriction strategy: histamine H3 and/or H4 receptor ligands with the 2,3-methanobutane backbone.
    Watanabe M; Kobayashi T; Hirokawa T; Yoshida A; Ito Y; Yamada S; Orimoto N; Yamasaki Y; Arisawa M; Shuto S
    Org Biomol Chem; 2012 Jan; 10(4):736-45. PubMed ID: 22120611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the binding site of the histamine H3 receptor. 1. Various approaches to the synthesis of 2-(1H-imidazol-4-yl)cyclopropylamine and histaminergic activity of (1R,2R)- and (1S,2S)-2-(1H-imidazol-4-yl)-cyclopropylamine.
    De Esch IJ; Vollinga RC; Goubitz K; Schenk H; Appelberg U; Hacksell U; Lemstra S; Zuiderveld OP; Hoffmann M; Leurs R; Menge WM; Timmerman H
    J Med Chem; 1999 Apr; 42(7):1115-22. PubMed ID: 10197956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the bioactive conformation of histamine H3 receptor antagonists by the cyclopropylic strain-based conformational restriction strategy.
    Watanabe M; Hirokawa T; Kobayashi T; Yoshida A; Ito Y; Yamada S; Orimoto N; Yamasaki Y; Arisawa M; Shuto S
    J Med Chem; 2010 May; 53(9):3585-93. PubMed ID: 20397706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of conformationally restricted analogs of baclofen, a potent GABAB receptor agonist, by the introduction of a cyclopropane ring.
    Shuto S; Shibuya N; Yamada S; Ohkura T; Kimura R; Matsuda A
    Chem Pharm Bull (Tokyo); 1999 Aug; 47(8):1188-92. PubMed ID: 10478475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and Stereostructure-Activity Relationship of Novel Pyrethroids Possessing two Asymmetric Centers on a Cyclopropane Ring.
    Taniguchi T; Taketomo Y; Moriyama M; Matsuo N; Tanabe Y
    Molecules; 2019 Mar; 24(6):. PubMed ID: 30875844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and characterization of some new C2 symmetric chiral bisamide ligands derived from chiral Feist's acid.
    Al Majid AM; Islam MS; Al-Othman ZA; Al-Salhoob AF; Barakat A
    Molecules; 2012 May; 17(5):5550-63. PubMed ID: 22572937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists.
    Ali SM; Tedford CE; Gregory R; Handley MK; Yates SL; Hirth WW; Phillips JG
    J Med Chem; 1999 Mar; 42(5):903-9. PubMed ID: 10072687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A convenient chemo-enzymatic synthesis and 18F-labelling of both enantiomers of trans-1-toluenesulfonyloxymethyl-2-fluoromethyl-cyclopropane.
    Riss PJ; Rösch F
    Org Biomol Chem; 2008 Dec; 6(24):4567-74. PubMed ID: 19039365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of Chiral cis-Cyclopropane Bearing Indole and Chromone as Potential TNFα Inhibitors.
    Kanada R; Tanabe M; Muromoto R; Sato Y; Kuwahara T; Fukuda H; Arisawa M; Matsuda T; Watanabe M; Shuto S
    J Org Chem; 2018 Aug; 83(15):7672-7682. PubMed ID: 30004223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of a series of 3,4-methanoarginines as side-chain conformationally restricted analogues of arginine.
    Watanabe M; Yamaguchi K; Tang W; Yoshida K; Silverman RB; Arisawa M; Shuto S
    Bioorg Med Chem; 2011 Oct; 19(20):5984-8. PubMed ID: 21917467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of cyclopropane-based conformationally restricted GABA analogues as selective inhibitors for betaine/GABA transporter 1.
    Suemasa A; Watanabe M; Kobayashi T; Suzuki H; Fukuda H; Minami M; Shuto S
    Bioorg Med Chem Lett; 2018 Nov; 28(20):3395-3399. PubMed ID: 30177378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxami de, an efficient noncompetitive N-methyl-D-aspartic acid receptor antagonist.
    Shuto S; Ono S; Hase Y; Ueno Y; Noguchi T; Yoshii K; Matsuda A
    J Med Chem; 1996 Nov; 39(24):4844-52. PubMed ID: 8941398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclopropane-based conformational restriction of GABA by a stereochemical diversity-oriented strategy: identification of an efficient lead for potent inhibitors of GABA transports.
    Nakada K; Yoshikawa M; Ide S; Suemasa A; Kawamura S; Kobayashi T; Masuda E; Ito Y; Hayakawa W; Katayama T; Yamada S; Arisawa M; Minami M; Shuto S
    Bioorg Med Chem; 2013 Sep; 21(17):4938-50. PubMed ID: 23886812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological activity of conformationally restricted analogues of milnacipran: (1S, 2R)-1-phenyl-2-[(R)-1-amino-2-propynyl]-N,N- diethylcyclopropanecarboxamide is a novel class of NMDA receptor channel blocker.
    Shuto S; Ono S; Imoto H; Yoshii K; Matsuda A
    J Med Chem; 1998 Aug; 41(18):3507-14. PubMed ID: 9719604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of novel 4(5)-(5-aminotetrahydropyran-2-yl)imidazole derivatives and their in vivo release of neuronal histamine measured by brain microdialysis.
    Harusawa S; Kawamura M; Araki L; Taniguchi R; Yoneyama H; Sakamoto Y; Kaneko N; Nakao Y; Hatano K; Fujita T; Yamamoto R; Kurihara T; Yamatodani A
    Chem Pharm Bull (Tokyo); 2007 Aug; 55(8):1245-53. PubMed ID: 17666853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pd(II)-Catalyzed Alkylation of Tertiary Carbon via Directing-Group-Mediated C(sp(3))-H Activation: Synthesis of Chiral 1,1,2-Trialkyl Substituted Cyclopropanes.
    Hoshiya N; Takenaka K; Shuto S; Uenishi J
    Org Lett; 2016 Jan; 18(1):48-51. PubMed ID: 26654827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.